Tessie Che, Ph.D.
Chairperson and General Manager
Tessie Che has served on the BOD and as GM of Amaran Biotech since 2013. She is also a director on the BOD of OBI Pharma USA, which is a wholly owned subsidiary of OBI Pharma, Inc (Taiwan). She co-founded Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR, based in San Diego, USA) and was OPTR’s head of operations from 1998-2011. In 2001, she co-founded OBI Singapore, which later became OBI Taiwan. During her tenure at Optimer Pharmaceuticals, Inc., she led the CMC (Chemistry, Manufacturing and Control) teams through early-stage development of the antibiotic drug, DIFICID® (Fidaxomicin) to its successful registration and commercialization in the US, Canada and Europe. Dr. Che also oversaw the clinical production of the cancer vaccine (referred to as OBI-822/OBI-821) from 2002-2005 while at Optimer Pharmaceuticals Inc.. Asian rights for OBI-822/OBI-821 were originally sublicensed to OBI Taiwan in 2003, and then in 2009, the world-wide license was transferred to OBI.
Dr. Che has had extensive scientific, manufacturing and business management experience in pharmaceutical and biotechnology industries, as well as served on different boards of directors in the industry. Prior to Optimer, her career history includes technical and executive positions at small and large companies such as Exxon Mobil, Aventis, Enichem, Pharmanex (Nuskin), M&D Precision Science Group and Cinogen (China).
Dr. Che obtained her B.S. Chemistry from Fu-Jen University (Taiwan) and Illinois State University (USA) and her Ph.D. Chemistry from Brandeis University (USA). She also carried out postdoctoral research at Columbia University (USA). She has 25 U.S. Patents and over 20 scientific publications in kinetics and material science.